Recall 2019-012: Solco - Irbesartan - NYC - Consumer
URGENT!!! DRUG RECALL!!! URGENT!!!
|Description ||Lot # || Exp Date || NDC || UPC|
|IRBES/HCTZ TB150/12.5MGSOLC30@ ||325D18005 ||3/31/2021 ||43547033003 ||34354733003|
| ||325D18004 ||3/31/2021 || || |
|IRBESARTAN TAB 300MG SOLC 90@ ||331B18009 ||2/28/2021 ||43547037609 ||34354737609|
|IRBESART-HCTZ300/12.5MGSOLC30@ ||327A18002 ||3/31/2021 ||43547033103 ||34354733103|
| ||327A18001 ||3/31/2021 || || |
|IRBESART-HCTZ300/12.5MGSOLC90@ ||327B18009 ||3/31/2021 ||43547033109 ||34354733109|
| ||327B18008 ||3/31/2021 || || |
|IRBES-HCTZ CP 150/12.5MGSOL90@ ||325B18004 ||3/31/2021 ||43547033009 ||34354733009|
Solco Healthcare is voluntarily recalling the above items/lots due to the detection of trace amount on an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. This recall is to the Consumer level. Affected product started shipping July 10, 2018.
Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on Irbesartan should continue taking their medication, until their pharmacist provides a replacement, or their doctor prescribes a different medication that treats the same condition as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
This recall is being conducted with the knowledge of the FDA.
Stericycle: Stericycle Solco Healthcare 888-871-7116